共查询到20条相似文献,搜索用时 0 毫秒
1.
细胞色素P450(cytochrome P450,CYP)是重要的药物代谢酶,参与催化多种内源和外源化合物,特别是多种临床药物的生物转化。CYP存在广泛的基因多态性和表型多态性,使其对于各种化合物的代谢存在统计学个体差异。核受体是配体依赖性转录因子超家族,与药物代谢过程中的基因表达调控密切相关,被外源物质活化后诱导或抑制CYP基因的表达。现综述CYP与药物代谢、CYP的基因多态性、CYP表达的诱导机制、核受体及其配体诱导CYP表达及近年研究CYP450的各种实验方法。 相似文献
2.
文拉法辛与细胞色素P450酶的相关性研究进展 总被引:1,自引:0,他引:1
文拉法辛是具有5-HT和NE双重再摄取抑制作用的新型抗抑郁药,与文拉法辛代谢密切相关的2种酶是CYP3A4和CYP2D6。CYP2D6将其生物转化为主要的活性代谢产物——O-去甲基文拉法辛(ODV),同时CYP3A4将文拉法辛转化为非活性代谢产物N-去甲基文拉法辛(NDV)。在常规治疗剂量下文拉法辛对于CYP3A4缺乏明显的诱导或抑制作用。而CYP2D6的活性直接影响文拉法辛和ODV的代谢和浓度,由于CYP2D6存在着基因遗传多态性,不同表型有着不同的文拉法辛代谢能力,而慢代谢者更易发生不良反应。研究证实文拉法辛与ODV的浓度比log(VENL/ODV)可作为异常代谢的指标,较简便地发现大多数异常基因型患者。 相似文献
3.
细胞色素P450氧化还原酶(Cytochrome P450 0xidoreductase,POR)是将电子从NADPH转运至所有肝微粒体的细胞色素P450氧化酶(Cytochrome P450 monooxygenases,CYP)中的唯一供体.药物、类固醇激素等物质的代谢和转化需要CYP参与.POR基因具有遗传多态性,遗传变异可以改变CYP活性,引起P450氧化还原酶缺陷(P450 0xidoreductase deficiency,PORD)、临床药物代谢和反应差异.本文将从POR的结构功能、基因突变引起的疾病及其对酶活性影响三个方面进行论述,总结近年来POR遗传多态性对CYP酶影响的最新研究进展. 相似文献
4.
CYP450氧化还原酶的遗传多态对药物代谢的影响 总被引:3,自引:1,他引:2
CYP450氧化还原酶(cytochrome P450 oxidoreductase,POR)是所有肝微粒体的细胞色素P450氧化酶(cytochrome P450 monooxygenases,CYP)的唯一电子供体,其中一些CYP是I相药物代谢酶,负责临床上超过80%药物的氧化代谢。另外,POR直接介导了一些抗肿瘤前体药物的代谢。因此,POR的遗传多态引起其活性的改变,对临床药物代谢具有非常重要的临床意义。该文总结了近年来POR的遗传多态影响药物代谢的最新研究进展。 相似文献
5.
细胞色素P450与药物代谢的研究现状 总被引:15,自引:8,他引:15
细胞色素P450(CYP)在众多中西药物代谢中起着非常重要的作用。本文综述了与药物代谢相关的CYP亚型、CYP与药物相互作用的关系及中药对CYP的影响,旨在合理解释和预测临床上药物间相互作用和药物不良反应等。同时选择适当的药物作为探针来评价CYP的活性,为实现临床个体化给药提供科学依据。 相似文献
6.
7.
酮康唑对大鼠肝脏CYP450酶系的影响* 总被引:3,自引:0,他引:3
目的:观察酮康唑对大鼠肝细胞色素P450及其主要亚型的影响。方法:Sprague-Dawley大鼠用140,280,420μmol.kg-1.d-1酮康唑连续灌胃7 d,测定肝脏微粒体中总CYP450含量和CYP1A1,1A2,1B1,2B1/2,2E1和3A亚型活性。结果:不同剂量酮康唑给药后大鼠肝脏脏器系数、CYP1A1和1B1亚型活性明显增高(P<0.05,P<0.01);总CYP450含量和CYP3A活性显著降低(P<0.01);低剂量的酮康唑抑制CYP1A2和CYP2B1/2亚型的活性,高剂量却出现了诱导作用(P<0.05,P<0.01)。各剂量组对CYP2E1均无明显影响。结论:酮康唑对大鼠肝脏CYP450及主要药物代谢亚型CYP1A1,1A2,1B1,2B1/2和3A有影响,临床长期用药或与经肝脏CYP450代谢的药物联合应用时要注意监测血药浓度和肝脏功能,防止药物代谢减缓出现蓄积中毒或药物代谢加快而降低药效。 相似文献
8.
细胞色素P450氧化还原酶的研究进展 总被引:7,自引:4,他引:7
细胞色素P450氧化还原酶(Cytochrom e P450 Reduc-tase,CPR)是细胞色素P450药物代谢酶系中为细胞色素P450提供电子的膜蛋白,本文从电子传递、底物作用及其基因调控三方面的特性对其进行了论述,并探讨了CPR领域一些待研究的问题。 相似文献
9.
10.
《Drug metabolism and pharmacokinetics》2018,33(1):55-60
Interindividual and interethnic variability of drug responses could be attributed to the differences of genetic polymorphisms in the drug metabolizing enzymes and transporters genes among the populations. Here we reviewed the studies of genetic variations in Uyghur Chinese of fifteen CYP450 genes including CYP1A1, CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP2J2, CYP2W1, CYP3A4, CYP3A5, CYP4A11, and CYP17A1, which totally covered 277 variants. We also collected the data of 277 variants covered in our study in two extensive population sequencing projects, the International HapMap Project (Hap-Map) and the 1000 Genomes Project and compared them with the data of Uyghur Chinese. The results suggested that remarkable differences of variants allele frequencies of CYP450 genes were existed among Uyghur Chinese and other world populations and drug doses should be adjusted clinically in Uyghur in contrast to Han Chinese and Caucasians. 相似文献
11.
细胞色素P450调节剂对DNA加合物形成的影响 总被引:1,自引:0,他引:1
人羊膜上皮细胞FL系分别接触a-萘黄酮(0.6mmol·L ̄(-1))β-萘黄酮(20pmol·L ̄(-1))24h后,再用苯并(a)芘[B(a)P,10umol·L ̄(-1)]处理24h,用32P后标记技术测定以B(a)-DNA加合物。结果发现,阳性对照组,a-萘黄酮预处理组及β-萘黄酮预处理组加合物的量分别为(加合物个数/10’个核苷酸):4.7±0.2(100%),1.8±0.9(38.3%),16.0±2.2(340.1%).该实验结果直接显示了纳胞色素P450调节剂对肿瘤发生影响的作用水平。亦为药物对致癌物代谢影响的研究提供了一种方法. 相似文献
12.
13.
细胞色素氧化酶P450(CYP)是最重要的药物代谢酶,多种中药能抑制或诱导CYP3A, CYP2C等亚型活性,而影响中药代谢,其中抑制作用是药物不良反应的主要原因;CYP1A2和CYP2E1等参与了中药前毒物的活化引起毒性反应。CYP参与中药代谢性相互作用,故可通过对CYP抑制或诱导作用的分析,研究中药配伍减毒作用或配伍禁忌的毒性(增毒)作用;应重视研究中西药合用引起不良反应的CYP作用。本文综述了CYP在中药毒性研究中的应用概况,进一步展望CYP的应用前景,以期对中药毒性研究提供新思路。 相似文献
14.
Cancer treatment and pharmacogenetics of cytochrome P450 enzymes 总被引:3,自引:0,他引:3
van Schaik RH 《Investigational new drugs》2005,23(6):513-522
Summary For the treatment of cancer, the window between drug toxicity and suboptimal therapy is often narrow. Interindividual variation
in drug metabolism therefore complicates therapy. Genetic polymorphisms in phase I and phase II enzymes may explain part of
the observed interindividual variation in pharmacokinetics and pharmacodynamics of anticancer drugs. The cytochrome P450 superfamily
is involved in many drug metabolizing reactions. Information on variant alleles for the different isoenzymes of this family,
encoding proteins with decreased enzymatic activity, is rapidly growing. The ultimate goal of ongoing research on these enzymes
would be to enable pharmacogenetic screening prior to anticancer therapy. At this moment, potential clinically relevant application
of CYP450 pharmacogenetics for anticancer therapy may be found for CYP1A2 and flutamide, CYP2A6 and tegafur, CYP2B6 and cyclophosphamide, CYP2C8 and paclitaxel, CYP2D6 and tamoxifen, and CYP3A5. For this latter enzyme, the drugs of interest still need to be identified. 相似文献
15.
16.
《Biopharmaceutics & drug disposition》2017,38(9):553-556
Acetylshikonin is a biologically active compound with anti‐cancer and anti‐inflammatory activity, which is isolated from the roots of Lithospermum erythrorhizoma . An inhibitory effect of acetylshikonin against CYP2J2 activity was discovered recently. Based on this result, this study was expanded to evaluate the inhibitory effects of acetylshikonin against nine different cytochrome P450 (P450) isoforms in human liver microsomes (HLMs) using substrate cocktails incubation assay. Acetylshikonin showed a strong inhibitory effect against all P450s tested with IC50 values of 1.4–4.0 μ m . Pre‐incubation of acetylshikonin with HLMs and NADPH did not alter the inhibition potency, indicating that acetylshikonin is not a mechanism‐based inhibitor. SKF‐525A, a widely used non‐specific P450 inhibitor, had no inhibitory activity against CYP1A2, 2A6, 2E1 and 2J2, while it showed an inhibitory effect against CYP2B6, CYP2C19 and 2D6 with IC50 values of 2.5, 3.6 and 0.5 μ m , respectively. Our findings indicate that acetylshikonin may be a novel general P450 inhibitor, which could replace SKF‐525A. 相似文献
17.
人细胞色素P450同工酶探针底物特异性的研究进展 总被引:7,自引:3,他引:7
细胞色素P450(CYP450)同工酶活性测定可用于药物/毒物代谢、药物相互作用和代谢多态性等研究,探针底物的特异性和实验条件的合理性对CYP450同工酶活性测定的准确性有着极其重要的意义。该文就近年来常用和新出现的CYP450同工酶探针底物的研究进展作一综述和评价。 相似文献
18.
The novel antifungal agent PLD-118 is neither metabolized by liver microsomes nor inhibits cytochrome P450 in vitro 总被引:1,自引:0,他引:1
Parnham MJ Bogaards JJ Schrander F Schut MW Oresković K Mildner B 《Biopharmaceutics & drug disposition》2005,26(1):27-33
PLD-118 is a novel, oral antifungal drug, under development for the treatment of Candida infections. Possible metabolism of PLD-118 by rat, dog and human S9 liver homogenates and inhibition of human cytochrome P450 (CYP) enzymes were investigated. PLD-118 (10 and 100 microM) incubated for 0-60 min with S9 fractions and NADPH was determined by HPLC, using the Waters AccQ.Tag method after derivatization of amino acids to stable, fluorescent derivatives. CYP assays were performed using pooled human liver microsomes with substrates, selective towards human CYP1A2, CYP2A6, CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP2E1 and CYP3A, incubated at concentrations around the Km. Incubation mixtures were preincubated with PLD-118 (0.1-100 microM) or control inhibitor for 5 min. No metabolism of PLD-118 was detected with rat and dog S9 fractions. A small (8%) decrease in PLD-118 at 100 microM (not detected at 10 microM) with human microsomes was considered to be biologically irrelevant. PLD-118 did not inhibit any of the tested CYPs. PLD-118, at concentrations up to 100 microM, is not metabolized by rat, dog or human liver S9 homogenates and does not inhibit human CYPs in vitro, suggesting little likelihood for interaction of PLD-118 with drugs metabolized by these enzymes. 相似文献
19.
Characterization of cytochrome P450 isoenzymes in primary cultures of pig hepatocytes 总被引:3,自引:0,他引:3
M. Monshouwer G.A.E. van't Klooster S.M. Nijmeijer R.F. Witkamp A.S.J.P.A.M. van Miert 《Toxicology in vitro》1998,12(6):715-723
Despite the fact that pigs are increasingly used in pharmacological and toxicological studies, knowledge on the enzymes which metabolize xenobiotics, in particular cytochrome P450 (CYP) enzymes, in pigs is still very limited. Primary cultures of pig hepatocytes were used to characterize CYP enzymes. The characterization was performed at the level of enzymatic activities, apoprotein and mRNA analyses. Enzyme inducers investigated were β-naphthoflavone (BNF), phenobarbital (PB), dexamethasone (DEX) and rifampicin (RIF). After 48 hr of BNF treatment, CYP1A protein and mRNA levels were increased, and ethoxyresorufin O-deethylation and caffeine 3-demethylation were strongly induced. PB and RIF increased the levels of CYP3A apoprotein and mRNA, whereas BNF down-regulated CYP3A and related activities. PB and RIF treatment resulted in increased ethylmorphine N-demethylation and testosterone hydroxylation, which appears to be the result of CYP3A induction. Hybridization of pig RNA with a human CYP2C9 cDNA probe showed a PB and RIF inducible CYP, which was down-regulated by BNF. Similar inducing effects were observed for tolbutamide, a marker substrate for CYP2C. DEX was not a potent inducer, although some induction of CYP3A mRNA was observed. The present results indicate the absence of CYP2B and probably CYP2D enzymes and activities in pig liver. Despite some dissimilarities, the results indicate that pigs, apart from their very human-like physiology, might represent a more appropriate model species for oxidative drug metabolism in humans than rats. 相似文献
20.
肝细胞微粒体的制备和细胞色素P450氧化酶活性测定 总被引:9,自引:0,他引:9
目的:为测定人肝细胞微粒体细胞色素P450氧化酶的活性。方法:用差速离心法制备3例人肝细胞微粒体。结果:细胞色素P450的含量为0.523±0.005nmol·mg-1;细胞色素b5为0.285±0.025nmol·mg-1;氨基比林N-脱甲基酶的活力为0.5±0.6nmol·mg-1;乙基吗啡N-脱甲基酶活力为0.98±0.08nmol·mg-1。结论:P450酶活性影响因素较多,个体差异大。临床用药时应考虑患者的个体情况。 相似文献